These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34018639)

  • 1. Two cases of advanced cutaneous squamous cell carcinoma lesions on the head and neck successfully treated with nivolumab.
    Ishiguro A; Ogata D; Namikawa K; Takahashi A; Yamazaki N
    J Dermatol; 2021 Sep; 48(9):e434-e435. PubMed ID: 34018639
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
    Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
    Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck.
    Parast L; Tian L; Wei LJ
    JAMA Oncol; 2024 Jan; 10(1):142-143. PubMed ID: 37991750
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck.
    Klein O
    JAMA Oncol; 2024 Jan; 10(1):143-144. PubMed ID: 37991743
    [No Abstract]   [Full Text] [Related]  

  • 5. Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region.
    Izumi T; Teramoto Y; Kamimura A; Doi R; Takai S; Mori T; Koizumi S; Kawahara Y; Aitake U; Lei X; Inomata N; Inafuku K; Nakamura Y
    J Dermatol; 2024 Feb; 51(2):271-279. PubMed ID: 38009848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply.
    Harrington KJ; Haddad R
    JAMA Oncol; 2024 Jan; 10(1):144-145. PubMed ID: 37991775
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
    Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany.
    Singh P; McDonald L; Waldenberger D; Welslau M; von der Heyde E; Gauler T; Dietz A
    Head Neck; 2021 Nov; 43(11):3540-3551. PubMed ID: 34487397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
    Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
    J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial.
    Ferrarotto R; Nagarajan P; Maronge JM; Johnson JM; Rosenthal DI; Myers JN; Gross ND
    JAMA Otolaryngol Head Neck Surg; 2023 Sep; 149(9):847-849. PubMed ID: 37535378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
    Ueda Y; Okano S; Enokida T; Fujisawa T; Ito K; Sato M; Tanaka H; Wada A; Tahara M
    Oral Oncol; 2022 Jul; 130():105932. PubMed ID: 35636078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
    Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
    Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
    Yen CJ; Kiyota N; Hanai N; Takahashi S; Yokota T; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Li WSK; Ferris RL; Gillison M; Endo T; Jayaprakash V; Tahara M
    Head Neck; 2020 Oct; 42(10):2852-2862. PubMed ID: 32583557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of advanced cutaneous squamous cell carcinoma of the lower eyelid that was successfully treated with tegafur-gimeracil-oteracil potassium monotherapy.
    Yamamoto Y; Nakai N; Wakabayashi Y; Okuzawa Y; Asai J; Takenaka H; Katoh N
    J Am Acad Dermatol; 2012 Nov; 67(5):e233-4. PubMed ID: 23062933
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.
    Tam S; Gajera M; Luo X; Glisson BS; Ferrarotto R; Johnson FM; Mott FE; Gillison ML; Lu C; Le X; Blumenschein GR; Wong MK; Rosenthal DI; Nagarajan P; El-Naggar AK; Midgen MR; Weber RS; Myers JN; Gross ND
    Head Neck; 2021 May; 43(5):1592-1603. PubMed ID: 33522021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
    Kiyota N; Hasegawa Y; Takahashi S; Yokota T; Yen CJ; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Sum Kenneth Li W; Ferris RL; Gillison M; Namba Y; Monga M; Lynch M; Tahara M
    Oral Oncol; 2017 Oct; 73():138-146. PubMed ID: 28939066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
    Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
    Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.